A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Hyperbilirubinaemia
- Focus Adverse reactions
- Acronyms JASMINE205
- Sponsors InfaCare Pharmaceutical Corporation
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2018 Planned End Date changed from 1 Aug 2020 to 1 Apr 2020.
- 28 Feb 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Apr 2020.